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ABSTRACT
Objectives: To evaluate the impact of National
Institute for Health and Care Excellence (NICE)
guidance in January 2005 and subsequent trial
evidence on the adoption of percutaneous closure of
patent foramen ovale (PCPFO).
Methods: A retrospective time series study was
conducted using the Inpatient Hospital Episode
Statistics (HES) England. A total of 3801 patients, aged
≥18 and ≤60 years, who had PCPFO from 1 April
2006 to 31 March 2012 in England. Percentage change
annualised (PCA) in PCPFO procedure rates between
initial NICE guidance and publication of trial results
was analysed.
Results: Between Quarter 2, 2006 and Quarter 4,
2009, 2163 PCPFO procedures were performed, with
an increasing PCA of 48.4%. The procedure rate
peaked before the presentation of equivocal results
from the first randomised controlled trial (RCT) in late
2010, and declined between Quarter 4, 2009 and
Quarter 4, 2011 (PCA=−15.3%). Of more than 2300
patients recruited to three RCTs, only 71 were recruited
in English hospitals.
Conclusions: PCPFO was rapidly adopted after the
publication of initial NICE guidance despite the absence
of RCT evidence of efficacy. Very few English patients
participated in international RCTs of PCPFO,
suggesting that NICE recommendations also failed to
encourage the generation of RCT evidence.
INTRODUCTION
Patent foramen ovale is postulated to
increase the risk of ischaemic stroke/transi-
ent ischaemic attack (TIA) through the para-
doxical embolism mechanism which
accounted for about 32% of ischaemic
stroke/TIA.1 2 Percutaneous closure of
patent foramen ovale (PCPFO) is a relatively
new day case interventional procedure that
might reduce risk of the recurrence of
stroke/TIA with low complication rates.
Although rare, potential periprocedural
major complications of PCPFO include peri-
cardial tamponade (0.2%; 95% CI 0.1% to
0.2%), cerebrovascular events (0.2%; 95% CI
0.0% to 0.3%), device embolism requiring
surgery (0.1%; 95% CI 0.0% to 0.2%) and
retroperitoneal haematoma (0.1%; 95% CI
0.0% to 0.1%). Long-term major complica-
tions include arrhythmias (3.3%; 95% CI
1.1% to 5.5%), cerebrovascular events (1.5%;
95% CI 1.0% to 2.0%) and device throm-
bosis (0.7%; 95% CI 0.4% to 1.0%).3
In 2005, despite lack of randomised con-
trolled trial (RCT) evidence, the National
Institute for Health and Care Excellence
(NICE) interventional procedures guidance
recommended that PCPFO could be used in
the secondary prevention of stroke/TIA with
audit and further research of safety and
KEY QUESTIONS
What is already known about this subject?
▸ In January 2005, National Institute for Health
and Care Excellence (NICE) guidance recom-
mended that percutaneous closure of patent
foramen ovale (PCPFO) could be used in the
secondary prevention of stroke/transient ischae-
mic attack for audit or research purposes,
despite lack of evidence from randomised con-
trolled trials (RCTs).
What does this study add?
▸ PCPFO had been rapidly adopted with a percent-
age change annualised of 48.4% in the first
4 years since initial NICE guidance.
▸ RCTs of PCPFO have struggled to recruit, only a
small number of English centres and patients
contributed to RCTs.
▸ The increased adoption of PCPFO after initial
NICE guidance despite the absence of RCT evi-
dence suggests that NICE guidance on PCPFO
encouraged premature adoption of PCPFO and
may have stifled generation of RCT evidence.
How might this impact on clinical practice?
▸ Clinicians must be cautious in embracing
nascent medical interventions until the safety
and efficacy of the medical interventions are
established.
▸ Greater clinicians’ participation is needed in the
recruitment of patients into RCT.
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efﬁcacy.4 Three RCTs5–7 published since 2010 compar-
ing PCPFO with medical therapy found some evidence
of reduction in the composite outcome of death or
stroke/TIA, but the results were not statistically signiﬁ-
cant. Meta-analyses that combine stroke and TIA out-
comes from these three RCTs ﬁnd weak evidence that
PCPFO is effective (eg, HR=0.59; 95% CI 0.36 to 0.97).8
Those that look at outcomes individually ﬁnd weaker evi-
dence (eg, HR=0.62; 95% CI 0.34 to 1.11)9 and tend to
reach more negative conclusions.10 11 Revised NICE
guidance in 2013 recommended that PCPFO was suit-
able for routine National Health Service (NHS) use.12
Our study aims to evaluate the impact of NICE guidance
in 2005 and dissemination of subsequent trial evidence
from 2010 on the adoption of PCPFO.
METHODS
A time series study was conducted. Quarterly data on
PCPFO procedure volumes from 1 April 2006 to 31
March 2012 was extracted from the English patient-level
Hospital Episode Statistics (HES) database managed by
the Health and Social Care Information Centre
(HSCIC). HES is a routinely collected data set that
records all day case or inpatient episodes of care pro-
vided to patients admitted to NHS hospitals and NHS
funded patients treated in independent sector hospitals
in England. A comprehensive synopsis of HES data is
available at http://www.hscic.gov.uk/hes. All index cases
were identiﬁed using the relevant (K16.5: Percutaneous
transluminal closure of patent foramen ovale with pros-
thesis) Ofﬁce of Population Census and Surveys (OPCS)
procedure code V.4.3.13 To identify cases of PCPFO for
secondary prevention of cryptogenic stroke/TIA, we
excluded patients aged <18 years old and >60 years old
as these age groups were excluded from the RCTs5–7
and are more likely to have PCPFO due to indications
other than secondary prevention of stroke/TIA. In
order to estimate procedure rate trends after March
2012, we used the publicly available data provided by the
HSCIC14 to calculate the average quarterly number of
PCPFO procedures per year from 1 April 2006 to 31
March 2013. As these data are aggregated by HSCIC, we
were not able to exclude patients based on age in this
analysis. We calculated percentage change annualised
(PCA) to summarise the diffusion of PCPFO procedures
in England over time.15 We used Joinpoint trend analysis
software to estimate the quarterly percentage change
(QPC) in procedure counts and test for changes in that
trend during the study period.16 The software ﬁts a pie-
cewise regression using weighted least squares with
Poisson variance and a grid search method to identify
between 0 and 3 joinpoints.
RESULTS
Study sample
From the individual patient data, we identiﬁed a total of
4388 PCPCO procedures between 1 April 2006 and 31
March 2012. A total of 587 patients aged <18 years old
and >60 years were excluded, resulting in a ﬁnal study
cohort of 3801 patients. PCPFO was used in 1897
(49.9%) men and 1903 (50.1%) women with a mean
age of 42.6 (SD=10.2) years (table 1). A further 688
patients of all ages had PCPFO between 1 April 2012
and 31 March 2013.
Trends in the adoption of PCPFO
Between the start of the study period (Q2, 2006) and the
peak in procedure volume (Q4, 2009), 2163 PCPFO pro-
cedures were performed, with a rapidly increasing PCA
of 48.4% (ﬁgure 1). In the remainder of the study period
(Q1, 2010 to Q1, 2012), 1638 PCPFO procedures were
performed. Between the peak (Q4, 2009) and the nadir
(Q4, 2011) after dissemination of initial trial results, the
PCA declined (PCA=−15.3%). Analysis of aggregate data
(without age exclusions) suggests that procedure rates
fell further during 2012/2013 (ﬁgure 1). Data after
March 2012 is an overestimate as it is based on national
data which does not restrict PCPFO to those ages
(18–60) thought most likely to be treated for cryptogenic
stroke/TIA. Joinpoint regression identiﬁed two inﬂection
points in procedure count trends. The initial rapid
increase in procedure counts (QPC=23.9; 95% CI 0.8 to
54.6) attenuated after Q1 2007 until Q4, 2009 (QPC=4.2;
95% CI 1.8 to 6.6) after which procedure rates declined
(QPC=−1.2; 95% CI 3.6 to 1.2).
The decline in procedure rates began before the
initial conference presentation of results from the ﬁrst
RCT, CLOSURE 1, in November 2010.17 CLOSURE 1
was published in March 2012, followed by RESPECT and
PC-Trial in March 2013. These trials randomised more
than 2300 patients; the only RCT (PC-Trial) that
recruited from European centres, included 71 patients
recruited from four English hospitals (Professor
Bernhard Meier, 2014).
DISCUSSION
After the publication of NICE guidance on PCPFO in
January 2005, the adoption of PCPFO rose rapidly
Table 1 Patients demographics (n=3801), 2006–2012
Demographics Number (%)
Sex
Male 1897 (49.91)
Female 1903 (50.07)
Age group
18–25 255 (6.71)
26–35 681 (17.92)
36–45 1257 (33.07)
46–60 1609 (42.33)
Race
White 2979 (78.37)
Others 244 (6.42)
Missing 578 (15.21)
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despite the lack of any RCT evidence of efﬁcacy. More
than 2000 procedures were performed before RCT
results became available in November 2010. Despite
NICE’s recommendation that PCPFO be used in audit
and with further research, only 71 patients from 4
English hospitals were randomised in the ﬁrst 3 RCTs of
PCPFO. The procedure rate peaked before the presenta-
tion of the equivocal results from the ﬁrst RCT.17 Since
then, the adoption of PCPFO had been falling until the
end of the study period in March 2013. It remains
unclear whether the current number of PCPFO proce-
dures is appropriate, however, there is clear evidence
that NICE guidance published in 2005 was associated
with premature adoption of PCPFO before the efﬁcacy
was established and without stimulating sufﬁcient
engagement with RCTs.
Premature adoption can be deﬁned as widespread
technology uptake without adequate evidence of relative
advantage, such as safety and cost-effectiveness. Adapted
from the Rogers’ S-shaped model of diffusion,18 the
Balliol Collaboration suggest the peak rate of surgical
innovation diffusion may occur once the ﬁrst 10–20% of
surgeons embrace the innovation and that the oppor-
tunity for formal assessment might then be lost.19 In this
context, it is notable that enrolment to the three pub-
lished PCPFO RCTs and other ongoing trials has lagged
considerably, prompting a call for greater engagement
among clinicians.20 Reasons for slow recruitment
include ‘off-label’ use of PCPFO in patients considered
too frail or with too many comorbidities for trial enrol-
ment21 as well as general clinician and patient barriers
to RCT recruitment.22
It is likely that some patients treated with PCPFO in
England were included in prospective registries and
observational studies; therefore contributed to knowl-
edge about adverse events and outcomes, although regis-
tries and observational studies are not well-suited for
establishing treatment effectiveness. In the UK, there
has been an ongoing effort to collect PCPFO complica-
tions and clinical outcome data through the establish-
ment of the Central Cardiac Audit Database12 and
recently the UK Percutaneous Patent Foramen Ovale
Closure in adults (PFOC) registry.23 However, we are not
aware of any peer-reviewed publications on PCPFO from
these data sources. To the best of our knowledge, there
had only been limited number of registries24 25 and
observational studies26–30 published from England, with
a total of 899 patients of 3801 patients in our study
cohort, highlighting the inefﬁciency in the enrolment of
NHS patients into research studies.
In the case of PCPFO and many other medical innova-
tions, premature adoption is encouraged by promising
results from observational studies.31 For example, a
meta-analysis study demonstrated that the HR of recur-
rent stroke in the three RCTs was 0.62 (95% CI 0.34 to
1.11) compared to 0.23 (95% CI 0.11 to 0.49) in obser-
vational studies of PCPFO,9 suggesting bias and overesti-
mation of the efﬁcacy of PCPFO in early cohort
studies.32 33 Other case studies of potential premature
adoption of cardiac interventional procedures include
transcatheter aortic valve implantation (TAVI),34 coron-
ary angiography and revascularisation.35
Our study has several limitations. First, we are unable
to estimate the proportion of the patients who had
PCPFO for the secondary prevention of ischaemic
stroke/TIA because of the suboptimal coding of previ-
ous diagnoses in the HES database.36 Nevertheless, we
believe that, after age criteria are applied, PCPFO for
the secondary prevention of stroke/TIA constitutes the
large majority of cases within our study. A large cohort
study on 207 PCPFO cases showed that secondary pre-
vention of cryptogenic stroke was the primary indication
for PCPFO (93%).37 Second, we are unable to show that
there is a temporal increase of PCPFO adoption with
NICE guidance implementation in 2005 due to unavail-
ability of PCPFO OPCS procedure code before April
2006. However, we believe that NICE guidance had
played a major role because it has been the intention of
NICE interventional programme guidance to encourage
and foster medical innovation.38 Third, we do not know
to what extent improved coding accuracy, for example
due to the introduction of payment by results hospital
reimbursement,39 might have contributed to the
increases in PCPFO procedure rates reported by hospi-
tals. Nevertheless, we believe that this effect is limited as
this reimbursement system was ﬁrst introduced in
Figure 1 Trends in the adoption
of percutaneous closure of patent
foramen ovale (PCPFO), 2006–
2013*. *Average quarterly
procedures (Q2, 2006 to Q1,
2013) based on aggregate data
on PCPFO procedures in patients
of all ages; quarterly procedures
(Q2, 2006 to Q1, 2012) based on
individual patient data on PCPFO
procedures in patients aged 18–
60 years only.
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2002.39 Finally, we cannot be certain whether the slow
decline in procedure rates between 2011 and 2013 solely
reﬂects caution among clinicians after the ﬁrst equivocal
RCT results or restrictions on funding introduced by
healthcare commissioners in times of economic auster-
ity. Although graphically the decrease of PCPFO adop-
tion does not seem to be temporally related to the
presentation of CLOSURE I results, we believe that the
presentation of the CLOSURE I results had at least to
some degree contributed to the decline, alongside with
these limitations due to the multifactorial causes of
PCPFO adoption.
Implications and conclusion
Premature adoption of unproven medical innovation is a
form of low value care as unproven medical device with
uncertain risk-to-beneﬁt ratio40 offers little or no net
clinical beneﬁts in relative to the alternative treat-
ments.41 It is an avoidable waste of healthcare resources
and worse still could be harmful to patients.42 Recent
scandals43 have prompted a change in the EU legislation
on medical devices whereby high quality evidence is
required for medium-risk and high-risk procedures
before market approval.44 Clinicians must be mindful of
embracing nascent medical technology until robust
unbiased evidence on the safety and efﬁcacy of new
medical technology is established. We recommend the
IDEAL framework in the evaluation of new medical
innovations.45 Evidence generation should follow the
hierarchy whereby the beginning of a RCT should mark
the end of reliance from observational studies to provide
evidence. Studies higher on the hierarchy of evidence,
such as RCTs, should be given priority to avoid competi-
tion for patient recruitment. Clinicians understandably
face challenges in RCT recruitment; support from pol-
icymakers and healthcare organisations are essential to
overcome these barriers.22 In cases where RCTs are not
possible due to rare events like in this case, observational
studies on postmarketing surveillance of the medical
devices are important to capture the outcome data to
determine if the beneﬁts of the medical device outweigh
the risks.46
In conclusion, PCPFO was rapidly adopted after the
publication of NICE guidance in 2005 despite the
absence of RCT evidence of efﬁcacy. Several thousand
patients had the procedure in England before
meta-analyses of three RCTs provided statistically weak
evidence on the efﬁcacy of PCPFO to reduce recurrent
stroke/TIA.47 A meta-analysis study which includes the
non-randomised studies demonstrated that there is an
increasing net clinical beneﬁts of PCPFO over time in
terms of stroke/TIA recurrence and bleeding risks com-
pared to the anticoagulant/antiplatelet therapies.48
Consequently, a personalised approach where the age of
patient, comorbidities, interaction with other medica-
tions should be considered when deciding if PCPFO or
medical therapy is suitable for a patient. NICE recom-
mendations contributed to premature adoption of
PCPFO and failed to encourage the timely generation of
RCT evidence. Further studies are required to investigate
the factors leading to premature adoption of new
medical innovation and how to prevent this
phenomenon.
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